Striving for a Multidisciplinary Approach for EoE: An Interview with Professor Gary Falk, University of Pennsylvania School of Medicine ‍

A robust pipeline of drugs has so far helped 30%-40% of patients. Clinical studies are exploring how non-drug therapies such as diet and cognitive behavioral therapy could help patients feel more in charge of their condition.

After decades of experience in hematology, Dr. Borate has repeatedly seen how blood diseases have the power to impact patients from head to toe. She’s currently excited by the potential of new, developing MDS testing tools that may help with earlier diagnosis.

Dr. Bejar is a physician-scientist who provides care to patients and also runs a research laboratory dedicated to studying MDS. He believes in individualized patient care, and sees multiple reasons to be hopeful for the future of MDS treatments.

In an interview, Dr. Ziad H. Younes of GastroOne highlighted the complexity of treating primary sclerosing cholangitis and some of the experimental treatments under development.

Dr. Phillips’ entire career has been dedicated to the field of inflammatory bowel diseases. Now that he’s entirely focused on physician education and participant recruitment for clinical trials, he is working to improve patient understanding of the life-changing potential that trials hold.

Dr. Merchant has dedicated her 30+ year career to specializations in gastric and colon cancer. While balancing patient care with research, she’s cognizant of a widespread need for more diverse recruitment for the sake of today’s care and tomorrow’s potential.

Dr. Sayna Norouzi is the founder and director of the glomerular diseases clinics at Loma Linda University Medical Center and a principal investigator on multiple clinical trials in rare kidney disease. Whether in her clinic or on social media, her focus is the same: giving patients the information and options they need to advocate for themselves.

Dr. Arun Rajasekaran knew he wanted to spend his career on glomerular disease while he was still in medical school. Today, as a nephrologist and clinical trial investigator, he brings that same fascination to a field he believes is only beginning to show how complex, and how treatable, these diseases can be.